


UM-PKU

Frontiers Science Center Joint Symposium



**PRECISION
ONCOLOGY**

OMICS

27

November 2024



澳門大學
UNIVERSIDADE DE MACAU
UNIVERSITY OF MACAU



北京大學
PEKING UNIVERSITY

**University of Macau - Peking University
Frontiers Science Center
Joint Symposium**

27 November 2024

Table of Content

Table of Content	Page 1
Programme Rundown	Page 2
Talk Schedule	Page 3-4
Speakers' Biography	Page 5 - 17
Contact Information	Page 18

Programme Rundown

Date : 27 November 2024
Location : E4-G062, UM

Time	Event
08:30 – 09:00	Registration
09:00 – 09:25	Opening Ceremony 09:00 - 09:05 Welcome Remarks by UM Rector Yonghua SONG 09:05 - 09:10 Welcome Speech by Prof. Qimin ZHAN 09:10 - 09:15 Programme Introduction by Prof. Chuxia DENG 09:15 - 09:20 Souvenir Presentation 09:20 - 09:25 Group Photo
09:25 – 10:45	Scientific Talks (Session I)
10:45 – 11:10	Coffee Break and Poster Session
11:10 – 12:25	Scientific Talks (Session II)
12:40 – 14:00	Lunch Break
14:15 – 15:45	Scientific Talks (Session III)
15:45 – 17:00	Coffee break and Poster Session
17:00 – 18:15	Scientific Talks (Session IV)
18:15 – 18:30	Poster Award Presentation and Closing Remarks by Prof. Xin CHEN

Talk Schedule

Session I

Session Chairs: Prof. Chuxia DENG and Prof. Qimin ZHAN

Time	Talk
09:25 – 09:55	<i>Genomic Alternations and Molecular Features of Esophageal Squamous Cell Carcinoma</i> by Prof. Qimin ZHAN, Peking University
09:55 – 10:20	<i>YTHDF2 Deficiency in Anti-HCC CD8 T Cells Necessitates IKZF1/3 Targeting in Synergy with Immune Checkpoint Blockade</i> by Prof. Jiajie HOU, University of Macau
10:20 – 10:45	<i>Tumor Heterogeneity and Precision Medicine</i> by Prof. Ning ZHANG, Peking University
10:45 – 11:10	Coffee Break and Poster Session

Session II

Session Chairs: Prof. Jinjian LU and Prof. Ning ZHANG

11:10 – 11:35	<i>Engineering of Humanized Antibodies and Tumor Immunotherapy</i> by Prof. Qi ZHAO, University of Macau
11:35 – 12:00	<i>Revisiting BRCA1/2: New Insights into Tumorigenesis and Therapy</i> by Prof. Jiadong WANG, Peking University
12:00 – 12:25	<i>The Landscape of Immune Evasion in Breast Cancer</i> by Prof. Xiaofan DING, University of Macau

Session III

Session Chairs: Prof. Kathy LUO and Prof. Hongquan ZHANG

Time	Talk
14:15 – 14:45	<i>Strategies of Precision Therapy of Advanced Refractory and Drug-resistant Tumours</i> by Prof. Chuxia DENG, University of Macau
14:45 – 15:10	<i>Identification and Characterization of Novel Histone Acylations: Role in the Regulation of Cancer Progression</i> by Prof. Hongquan ZHANG, Peking University
15:10 – 15:35	<i>Reciprocal Stabilization of CtBP and TRIM28 by Forming Complex Promotes Cancer Metastasis via Repressing Autophagy</i> by Prof. Lijun DI, University of Macau
15:35 – 15:45	<i>Publishing with Wiley: An Advanced Perspective</i> by Dr. Xiaoyu ZHANG, Deputy Editor of <i>Advanced Science</i>
15:45 – 17:00	Coffee Break and Poster Session

Session IV

Session Chairs: Prof. Edwin CHEUNG and Prof. Jiadong WANG

17:00 – 17:25	<i>Investigation and Application of Neoantigen-reactive T Cells</i> by Prof. Chunhong ZHENG, Peking University
17:25 – 17:50	<i>Targeting TNFR2 in Cancer Immunotherapy: Recent Progress</i> by Prof. Xin CHEN, University of Macau
17:50 – 18:15	<i>H3K4me3 Regulates RNA Polymerase II Promoter-proximal Pause-release</i> by Prof. Hua WANG, Peking University
18:15 – 18:30	<i>Poster Award Presentation and Closing Remarks</i> by Prof. Xin CHEN, University of Macau

Speaker's Biography

Prof. Xin CHEN

Distinguished Professor, University of Macau
Director, Institute of Chinese Medical Sciences
Director, State Key Laboratory of Quality Research in Chinese Medicine



Prof. Xin CHEN was initially trained as clinician in Chinese medicine in Hubei University of Chinese Medicine, where he obtained bachelor and master's degrees in Chinese medicine. He earned a doctoral degree in Chinese Medicine from Guangzhou University of Chinese Medicine in 1991 and a PhD degree in Medical Sciences (immunology) from Radboud University Nijmegen (Netherlands) later. Prof. Chen began his postdoctoral training at the School of Pharmacy and Biomedical Sciences, University of Portsmouth, UK. In 1999 he joined the Laboratory of Molecular Immunoregulation, National Cancer Institute (NCI)-Frederick, National Institutes of Health (NIH), USA. He was a Scientist II in 2003 and then a Senior Scientist in SAIC-Frederick, Inc. and Leidos Biomedical Research, Inc. at NCI/NIH since 2001. He joined the University of Macau in 2014 as full professor. Currently, he is a distinguished professor and the director of the Institute of Chinese Medical Sciences, and interim director of the State Key Lab of Quality Research in Chinese Medicine. He is also a deputy editor of the *Journal of Leukocyte Biology*. He was an Attending Physician and then Deputy Chief Physician from 1991~1998 in Shenzhen 2nd People's Hospital, China. He was a Licensed Acupuncturist (and Diplomat of Acupuncture, NCCAOM) in the State of Maryland, USA, since 2004, and was a Licensed Doctor of Traditional Chinese Medicine in Macau since 2019.

Personal website:

<https://sklqrcm.um.edu.mo/xin-chen/>





Prof. Chuxia DENG

Dean of Faculty of Health Sciences, University of Macau
Chief Scientist of MoE Frontiers Science Center for Precision Oncology,
University of Macau
Chair Professor, University of Macau

Prof. Chuxia DENG is the Founding Dean of Faculty of Health Sciences and the Chief Scientist of MoE Frontiers Science Center for Precision Oncology, University of Macau. He received MS from Chinese Academy of Sciences in 1984, and PhD from University of Utah in 1992 under the supervision of Prof. Mario R. CAPECCHI, Winner of 2007 Nobel Prize in Physiology or Medicine. After his postdoctoral fellow training at Harvard Medical School, he has been Investigator, Senior Investigator and Chief of Mammalian Genetics Section, Genetics of Development and Disease Branch of National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) of National Institutes of Health (NIH), USA from 1995 to 2014. Prof. Deng has received numerous awards in recognition of his outstanding achievements in teaching and research, including the NIH-APAO Outstanding Achievement Award (2000, NIH), the Outstanding Overseas Scholar from National Science Foundation (2002, China), NIDDK "You Make A Difference Award" (2005, 2013), and the NIDDK Director's Award (2011). He was elected as a fellow of the American Association for the Advancement of Science (2012), topped the list in biology and biochemistry among all the Chinese scientists in the 2023 Best Scientists Ranking announced by Research.com, and named in Stanford University's World Top 2% Scientists 2024 for his career-long citation impact. He is the author or co-author of over 650 papers published in peer-reviewed journals. As at October 2024, Prof. Deng has an H-index at 149 with a total citation approximately 81,000. He is currently Editor-in-Chief of *International Journal of Biological Sciences*. Prof. Deng has long and successful track record in cancer research, with particular focuses lately on precision oncology, oncogenes and tumour suppressor genes, as well as gene targeting and drug development.

Personal website:

<https://fhs.um.edu.mo/en/staff/chuxia-deng/>





Prof. Lijun Di

Associate Professor, University of Macau

Prof. Lijun Di is currently an associate professor affiliated with the Department of Biological Sciences in Faculty of Health Sciences, University of Macau. Prof. Di graduated from Peking Union Medical College with a PhD degree in Beijing. From 2007 to 2012, he had his postdoc training in National Cancer Institute of USA. Prof. Di has the research interest of understanding the mechanisms involved in the development of diseases such as cancer, diabetes and obesity and intends to discover the novel therapeutic targets. His group has studied the relationship between the intracellular metabolic pathways and cancer development (*Cell death and diseases 2015, Oncogenesis 2017, Oncogene 2018*). His group has also studied the mechanisms in breast and ovarian cancer initiation, development and metastasis. The representative findings include distinguishing the cell origins of HGSOE, immune microenvironment and chemosensitivity study in ovarian cancer, the correlation study between Estrogen signaling and DNA damage repair in Ovarian cancer (*Clinical Cancer Research 2018,2019, Theragnostic 2020, International Journal of Biological Sciences, 2022*). In addition, his group also studied the etiology of obesity, and understood how obesity contributes to the type II diabetes phenotypes through regulating adipose tissue microenvironment such as inflammation, ER stress etc. to result in insulin resistance and glucose intolerance etc. (*Diabetes 2013, Journal of Biological Chemistry 2015, FASEB Journal 2018, Arteriosclerosis, Thrombosis, and Vascular Biology 2018*).

Personal website:

<https://fhs.um.edu.mo/en/staff/lijun-di/>





Prof. Xiaofan DING


Assistant Professor, University of Macau

Prof. Xiaofan DING received his PhD degree in Biochemistry from the Hong Kong University of Science and Technology in 2014, after which he joined The Chinese University of Hong Kong as a post-doctoral fellow. He became a research assistant professor in 2021 in the Department of Surgery at The Chinese University of Hong Kong. Prof. DING joined University of Macau in 2023. He is currently an assistant professor at the Faculty of Health Sciences, University of Macau. His research interests mainly focus on cancer genomics, intratumoral heterogeneity, functional genomics, cancer epigenetics and tumor immunity. His research in cancer genomics and intratumor molecular heterogeneity has recently been published in some prestigious journals such as *Journal of Hepatology* (2022), *Gastroenterology* (2019) and *Hepatology* (2019). To enhance the effectiveness of cancer immunotherapy, he is now conducting studies to unravel the tumor immune microenvironment in various cancer types. This research leverages data from different platforms, including single-cell transcriptomics, spatial transcriptomics and imaging mass cytometry data.

Personal website:

<https://fhs.um.edu.mo/en/staff/xiaofan-ding/>





Prof. Jiajie HOU

Assistant Professor, University of Macau

Prof. Jiajie HOU is a clinician researcher with ever-lasting interest in the field of inflammation, immunity and liver cancer. He obtained an MBBS degree (2009) and a PhD degree (2015) in Nanjing, and practised as a liver surgeon for 6 years at Shanghai Renji Hospital and Sun Yat-sen University Cancer Centre. In addition to his clinical expertise, Prof. Hou received cancer research training from the University of Chicago in the United States and QIMR Berghofer Medical Research Institute in Australia. He has published in high impact journals including *Hepatology* (2013, 2024), *Journal of Hepatology* (2014, 2020), *Molecular Cancer* (2019, 2024), *Nature Immunology* (2020), *Nature Reviews. Clinical Oncology* (2021), *Cancer Research* (2022), *Cell Metabolism* (2024), *Nature Communications* (2024), and received awards such as the Distinguished Young Scholar in Guangdong Province (2021). Supported by multiple grants, the Hou Lab is now dedicated to understand how therapy-induced inflammation influence liver cancer immunity and inspire combination immunotherapy.

Personal website:

<https://fhs.um.edu.mo/en/staff/jiajie-hou/>





Prof. Hua WANG

Assistant Professor, Peking University International Cancer Institute

Prof. Hua WANG is currently an assistant professor at the Peking University International Cancer Institute. He graduated from Soochow University in 2014 and earned his PhD from Nankai University in 2018. He then conducted postdoctoral research at the Memorial Sloan Kettering Cancer Center under the mentorship of Dr. Kristian HELIN, a prominent researcher in cancer epigenetics, and Dr. Xuejun JIANG, a pioneer in ferroptosis research field. In 2023, he joined the Peking University International Cancer Institute to establish his independent lab. His research focuses on elucidating the mechanisms of epigenetic and transcriptional regulation in cancer, with an emphasis on unraveling the molecular intricacies of how epigenetic factors contribute to tumorigenesis. His research findings have been published in prestigious journals, including *Nature*, *Trends in Cell Biology*, *Blood* and *Cell Research*.

Personal website:

https://sbms.bjmu.edu.cn/jsdw/bssds/Hua_Wang.html





Prof. Jiadong Wang

Boya Distinguished Professor, Peking University

Prof. Jiadong WANG, Peking University Boya Distinguished Professor, has long been devoted to the study of DNA damage repair and cancer, with a focus on the regulation of BRCA1/2 function and their roles in tumorigenesis and therapy. As corresponding author, Prof. Wang has published research papers in journals such as *The Journal of Clinical Investigation* (2024), *PNAS* (2024, 2020), *EMBO Journal* (2023) and *Molecular Cell* (2019) in the past five years, contributing to the comprehensive understanding of the precise regulatory network of DNA damage repair and its biological effects.

Personal website:

<http://jccx.bjmu.edu.cn/teacher/detail/t/MDAxNjE4MDA2Ng==>



Prof. Qimin ZHAN

Academician, Chinese Academy of Engineering
Peking University Boya Chair Professor,
Deputy Director, University Council
Dean, Peking University International Cancer Institute
and National Institute of Health Data Science at Peking University
Director and Chief Scientist, Frontiers Science Center for Cancer Integrative Omics
Director, Molecular Oncology Laboratory Beijing Cancer Hospital
Dean, School of Medicine, Suzhou University
Former Executive Vice President, Peking University



Prof. Qimin ZHAN has received Changjiang Scholarship of Ministry of Education. He is also a winner of the National Science Foundation for Distinguished Young Scholars and the national candidate of New Century Talent Project. He is a chief expert of Innovation Group of the National Natural Science Foundation of China, and a Chief scientist of the National Program on Key Basic Research Project of China (973 Program). He currently serves as Vice President of Chinese Medical Doctor Association, Vice Chairman of China Anti-Cancer Association, Vice President of China International Exchange and Promotive Association for Medical and Health Care, President of Chinese Society of Microcirculation, and Chairman of the Overseas Physicians division of the Western Returned Scholars Association. He was the Director of the Strategic Council for Biotechnology Development, Ministry of Science and Technology of the People's Republic of China, Deputy Director of Science and Technology Innovation Committee of National Health Commission, Convenor of the 8th Discipline Evaluation Group of the Academic Degrees Committee of The State Council, and Member of the Fifth Committee of National Science and Technology Awards. He has been engaged in the research of tumor molecular biology and translational medicine for a long time, and is responsible for the planning of the national development strategy of medical science and biotechnology. He has published more than 270 academic papers and 9 books in international journals of medical biology.

Personal website:

<https://www.bjmu.edu.cn/zggcyys/e7748e841a784d73a5be3e18d5209bda.htm>





Prof. Hongquan ZHANG

Tenured Full-Professor of Cancer Biology, Peking University
Deputy Director, Peking University International Cancer Institute
Chairman, Department of Human Anatomy, Histology and Embryology,
School of Basic Medical Sciences
President, Chinese Society for Cancer Metastasis

Prof. Hongquan ZHANG is a tenured full-professor of Cancer Biology at Peking University. He is currently Deputy Director of Peking University International Cancer Institute and Chairman of the Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences. He is the President of the Chinese Society for Cancer Metastasis. Prof. Zhang has published more than 140 peer-reviewed papers including some in leading journals. Prof. Zhang has trained more than 50 PhD students and 10 post-doctoral fellows in Karolinska Institutet and Peking University. Prof. Zhang's research interests are cancer invasion, metastasis, and drug resistance, cancer stem cells, protein post-translational modifications concerning cancer progression.

Personal website:

<https://sbms.bjmu.edu.cn/zzptxjys/kycgishfw/index.htm>



Prof. Ning ZHANG



Director, Translational Cancer Research Center, Peking University First Hospital
Deputy Director, International Cancer Institute at Peking University
Deputy Director, PKU-YNBY Joint Research Center
Chief Scientific Officer, Yunnan Baiyao Group
Principal Investigator, Cancer Hospital Research Institute at Tianjin Medical University
Executive Director and Deputy Secretary General, China Anti Cancer Association
Chairman, Journal Publishing Professional Committee of the China Anti Cancer Association
Former Chairman, Nanooncology Professional Committee
Executive Deputy Editor in Chief, *Cancer Biology & Medicine*
Deputy Editor in Chief, *Medical Review*
Professor, Peking University Health Science Center

Prof. Ning ZHANG has won the National Science Fund for Distinguished Young Scholars, the National "Ten Thousand Talents Program", the Ministry of Science and Technology's young and middle-aged scientific and technological innovation leader, the Ministry of Personnel's ten million talents, outstanding contribution experts, Tianjin outstanding talents, the Ministry of Education's new century outstanding talents, Tianjin's top ten outstanding returned overseas students, the Tianjin Youth Science and Technology Award winner, the American Lee's Foundation's outstanding achievement award winner, the first prize in science and technology of China Anti Cancer Association (2023), and the 13th Chinese People's Political Consultative Conference member of Tianjin.

Personal website:

<http://derm.pku.edu.cn/info/1102/1250.htm>



Dr. Xiaoyu ZHANG

Deputy Editor, *Advanced Science*
Manager for Publishing Development, Wiley



Dr. Xiaoyu ZHANG is the Deputy Editor of *Advanced Science* (IF: 14.4, Wiley's Influence series) and the Manager for Publishing Development of Wiley. He obtained his PhD in Biochemistry and Molecular Biology from East China Normal University and conducted the postdoctoral training at the University of Pittsburgh School of Medicine in USA. He joined Wiley in 2020 and since served as a full-time Scientific Editor for several life science and interdisciplinary journals, he has been involved in the launch and management of Wiley's materials and interdisciplinary partner journals in China. Since 2023, he has taken on the role of Deputy Editor at *Advanced Science* and serves as the Cluster Editor for the biomaterials/healthcare journals, overseeing manuscript solicitation and peer review processes.



Prof. Qi ZHAO

Associate Professor, University of Macau

Prof. Qi ZHAO obtained his Bachelor's degree from the College of Life Sciences at Jilin University and his PhD from the Department of Biochemistry at the Chinese University of Hong Kong. He conducted postdoctoral research at the National Cancer Institute (NCI) of the National Institutes of Health (NIH) in the United States and at the Memorial Sloan Kettering Cancer Center. He has served at the Faculty of Health Sciences, University of Macau since 2016. In recent years, he has published over 100 research papers and holds 20 patents, with publications in journals such as *Nature Communications*, *Leukemia*, *Journal of Hematology & Oncology*, and *Clinical Cancer Research*. He has received the NIH Federal Technology Transfer Award and is recognized as a high-level overseas talent in Shenzhen. Prof. Zhao has led various research projects, including the National Key R&D Program, the Macau Science and Technology Development Fund, the National Natural Science Foundation of China, the Novo Nordisk Joint Fund, and the Guangdong Provincial Key National Science and Technology Cooperation Fund. His research mainly focuses on antibody therapeutics against cancer.

Personal website:

<https://fhs.um.edu.mo/en/staff/qizhao/>



Prof. Chunhong ZHENG

Principal Investigator, Peking University International Cancer Institute



Prof. Chunhong ZHENG is the Principal Investigator at the Peking University International Cancer Institute. She earned her PhD from Peking University in China and furthered her research expertise through postdoctoral training at both Peking University and the Earle A. Chiles Research Institute of Providence Cancer Institute in USA. Prof. Zheng's research is centered on single-cell cancer immunology, where she employs single cell sequencing technology to investigate the composition, characteristics, and molecular signatures of tumor-infiltrating T cells, with a particular emphasis on tumor neoantigen-reactive T cells, with the ultimate goal of enhancing T-cell-based immunotherapies for cancer patients. Prof. Zheng has published several peer-reviewed papers in prestigious international journals such as *Cell*, *Cancer Cell*, and *Nature Medicine* as the first and corresponding author. Her work has been selected as "Cell Press Paper of the Year 2017, China" and "Top 10 Biological Science Breakthroughs in China of 2017." Moreover, Prof. Zheng has received the "National Science Fund for Excellent Young Scholars of China (Overseas)", the "First Prize of Natural Science Award of the Beijing Municipality for Science and Technology Awards of 2020", and the "2018 Jacques Dupont Memorial Research Fellowship".

Personal website:

<https://pkuici.bjmu.edu.cn/szdw/yjyPI/zch/index.htm>



Contact Information

Address:

Room 4045, Faculty of Health Sciences (E12) Building,
University of Macau,
Avenida da Universidade,
Taipa, Macao, China

Contacts:

Mr. Andrew LIU
Email: andrewliu@um.edu.mo
Tel: 853-8822 4201

Ms. Bibiana TANG
Email: bibianatang@um.edu.mo
Tel: 853-8822 4405

Ms. Dion HUANG
Email: dionhuang@um.edu.mo
Tel: 853-8822 4406

Ms. Chloe HO
Email: chloeho@um.edu.mo
Tel: 853-8822 9199

